Table 1 Descriptive statistics of clinical characteristics of assessed patients with AOSD and grouped according to the presence of LD
Clinical characteristics | 18 patients with LD | 129 patients without LD | P values, patients with LD vs patients without LD |
|---|---|---|---|
Age, mean ± SD | 53.6 ± 14.7 years | 44.0 ± 16.1 years | 0.017 |
Gender, n (%) | 9 (50.0) male | 80 (62.0) male | 0.441 |
Fever, n (%) | 18 (100.0) | 129 (100.0) | / |
Arthritis, n (%) | 16 (88.9) | 114 (88.4) | 0.654 |
Skin Rash, n (%) | 13 (72.2) | 97 (75.2) | 0.492 |
Myalgia, n (%) | 16 (88.9) | 79 (61.2) | 0.033 |
Splenomegaly, n (%) | 14 (77.8) | 84 (65.1) | 0.215 |
Lymph node involvement, n (%) | 14 (77.8) | 66 (51.2) | 0.028 |
Sore throat, n (%) | 12 (66.7) | 71 (55.0) | 0.450 |
Liver Involvement, n (%) | 11 (61.1) | 80 (62.0) | 0.567 |
Pleuritis, n (%) | 10 (55.5) | 19 (14.7) | < 0.001 |
Pericarditis, n (%) | 7 (38.9) | 24 (18.6) | 0.064 |
Abdominal Pain, n (%) | 8 (44.4) | 12 (9.3) | 0.001 |
Systemic score, mean ± SD | 8.4 ± 2.1 | 5.7 ± 1.8 | < 0.001 |
MAS, n (%) | 5 (27.8) | 21 (16.3) | 0.071 |
Leucocytosis > 15,000/mm3, n (%) | 11 (61.1) | 67 (51.9) | 0.318 |
ESR, mean ± SD | 70.7 ± 24.7 mm/hr | 69.2 ± 27.7 mm/hr | 0.821 |
CRP, median (interquartile range) | 113.1 (99.2) mg/L | 77.0 (79.6) mg/L | 0.080 |
Ferritin, median (interquartile range) | 3370.5 (3051.8) ng/mL | 2841.5 (3545.1) ng/mL | 0.010 |
Low dosage GCs (≤ 0.5 mg/kg/day), n (%) | 4 (22.2) | 57 (44.2) | 0.062 |
High dosage GCs (> 0.5 mg/kg/day), n (%) | 14 (77.8) | 72 (55.8) | 0.789 |
Synthetic DMARDs, n (%) | 11 (61.1) | 84 (65.1) | 0.464 |
Biologic DMARDs, n (%) | 5 (27.8) | 39 (30.2) | 0.536 |
Monocyclic disease pattern, n (%) | 4 (22.2) | 47 (36.4) | 0.510 |
Polycyclic disease pattern, n (%) | 3 (16.7) | 46 (35.6) | 0.044 |
Chronic disease pattern, n (%) | 4 (22.2) | 34 (26.3) | 0.479 |
Mortality, n (%) | 7 (38.9) | 13 (10.1) | 0.004 |
Time of follow-up, median (interquartile range) | 2.8 (3.4) years | 3.9 (3.4) years | 0.199 |